Cost-effectiveness in glaucoma. Concepts, results and current perspective

Guedes, Ricardo Augusto Paletta; Guedes, Vanessa Maria Paletta; Chaoubah, Alfredo

doi:10.5935/0034-7280.20160068

Cited by 6 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 Similar to report by Varma et al, 13 this study findings revealed that the financial burden of glaucoma increases as disease severity increases with time. Furthermore, as noted by Guedes et al, 21 since glaucoma is of genetic origin and cannot be prevented, early detection and diagnosis is the most cost-effective way of managing glaucoma and preventing blindness. Consistent with report by Ocansey et al, 5 this study found a statistically significant difference between the cost burden of glaucoma care and wealth status.…”

Section: Discussionmentioning

confidence: 99%

Economic cost of management of glaucoma in public and private health facilities in the Tema metropolis in Ghana

Adda,

Amon,

Nonvignon

et al. 2024

gmj

View full text Add to dashboard Cite

Objectives: This study sought to determine the economic cost of the management of glaucoma among patients seeking care in health facilities in Ghana.Design: A cross-sectional cost-of-illness (COI) study from the perspective of the patients was employed.Setting: The study was conducted in public and private eye care facilities in the Tema Metropolis of Ghana.Participants: About 180 randomly selected glaucoma patients seeking healthcare at two facilities participated in the study.Main outcome measure: Direct cost, including medical and non-medical costs, indirect cost, and intangible burden of management of glaucoma.Results: the cost per patient treated for glaucoma in both facilities was US$60.78 (95% CI: 18.66-107.80), with the cost in the public facilities being slightly higher (US$62.50) than the private facility (US$ 59.3). The largest cost burden in both facilities was from direct cost, which constituted about 94% of the overall cost. Medicines (42%) and laboratory and diagnostics (26%) were the major drivers of the direct cost. The overall cost within the study population was US$10,252.06. Patients paid out of pocket for the frequently used drug- Timolol, although expected to be covered under the National Health Insurance Scheme (NHIS). Patients, however, expressed moderate intangible burdens due to glaucoma.Conclusion: The cost of the management of glaucoma is high from the perspective of patients. The direct costs were high, with the main cost drivers being medicines, laboratory and diagnostics. It is recommended that the National Health Insurance Authority (NHIA) should consider payment for commonly used medications to minimize the burden on patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Economic cost of management of glaucoma in public and private health facilities in the Tema metropolis in Ghana

Adda,

Amon,

Nonvignon

et al. 2024

gmj

View full text Add to dashboard Cite

show abstract

“…Os estudos de custo-utilidade são importantes, pois avaliam tanto os custos como a qualidade de vida relacionados a uma determinada doença. (25) Tabela 4. Custos totais, utilidades (ano de vida ajustado pela qualidade) e análise de custo-utilidade.…”

Section: Discussionunclassified

Custo-utilidade do tratamento primário não farmacológico do glaucoma de ângulo aberto

Gravina¹,

Guedes²,

Chaoubah³

2023

Revista Brasileira De Oftalmologia

View full text Add to dashboard Cite

show abstract

“…The chronic use of hypotensive eye drops is one of the main factors responsible for the high cost of treating glaucoma 42–44 . In a developing country with scarce resources, a treatment that extends the introduction of eye drops for glaucoma can reduce the direct medical costs of the public health system 45 . Unlike the Light trial, which recruited only newly diagnosed patients, we decided to cover our study for patients who had already used the medications, thus observing an effect, in real life, of the reduction of eye drops and, consequently, direct costs to the Brazilian public system.…”

Section: Discussionmentioning

confidence: 99%

Selective Laser Trabeculoplasty as a Substitute for Medications in Patients with Mild-to-moderate Glaucoma in the Brazilian Public Health System

Barbosa,

Barboza,

Guedes

et al. 2023

Journal of Glaucoma

View full text Add to dashboard Cite

Précis: Selective laser trabeculoplasty can be used as a substitute for medications in patients with mild-to-moderate glaucoma, reducing the cost of eye drop distribution in the Brazilian public health system. Purpose: To observe the effectiveness of selective laser trabeculoplasty (SLT) as a substitute for eye drops in patients with open-angle glaucoma in the Brazilian Public Health System. Materials and methods: SLT was performed bilaterally after medication washout. This is a prospective interventional study, comparing intraocular pressure (IOP) when using eye drops, at baseline (post-washout), and at 12-month follow-up, after SLT. Medication was added if the target IOP was not achieved, following the Brazilian Public Health System eye drops protocol, based on medication costs. Absolute (without eye drops) and qualified (with eye drops) success were measured with IOP ≤ 21, IOP ≤ 18, IOP ≤ 15 and IOP ≤ 12 mmHg. Besides IOP evolution, ability to reduce IOP (in %), and eye drops reduction were evaluated. Results: 92 eyes of 46 patients were included, 70 eyes with mild glaucoma and 22 with moderate glaucoma, mean number of eye drops 2.26±1.06 (82.6% were using a prostaglandin analogue) and post-washout IOP of 21.10±5.24 mmHg. There was relative success at IOP ≤18 mmHg, where the mild group had greater success than the moderate group (88.1% vs. 71.4%, P=0.824). The average IOP reductions were 23.04% and 25.74% at 6 and 12 months, respectively. The average number of eye drops was 1.02, with 1.1% using a prostaglandin analogue. Furthermore, 68.19% of the patients had a decrease in the quantity of eye drops used. Conclusion: SLT is effective in reducing IOP and replacing eye drops in patients in the Brazilian Public Health System. Moreover, there was a significant reduction in the use of prostaglandin analogues.

show abstract

Cost-effectiveness in glaucoma. Concepts, results and current perspective

Cited by 6 publications

References 29 publications

Economic cost of management of glaucoma in public and private health facilities in the Tema metropolis in Ghana

Economic cost of management of glaucoma in public and private health facilities in the Tema metropolis in Ghana

Custo-utilidade do tratamento primário não farmacológico do glaucoma de ângulo aberto

Selective Laser Trabeculoplasty as a Substitute for Medications in Patients with Mild-to-moderate Glaucoma in the Brazilian Public Health System

Contact Info

Product

Resources

About